MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

Item
http://www.wikidata.org/entity/Q34507966
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiformeCodeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Curcumin Reactivates Silenced Tumor Suppressor Gene RARβ by Reducing DNA Methylation.Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression.Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.
P2860

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

Item
http://www.wikidata.org/entity/Q34507966
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@ast
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@en
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@nl
type
label
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@ast
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@en
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@nl
prefLabel
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@ast
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@en
MGMT promoter hypermethylation ...... correlated with TP53 mutation.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
MGMT promoter hypermethylation ...... correlated with TP53 mutation
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P932